CD20 x CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

被引：8

作者：

Liu, Xinyuan ^{[1
]}

Zhao, Juanjuan ^{[2
]}

Guo, Xiangqian ^{[1
]}

Song, Yongping ^{[2
]}

机构：

[1] Henan Univ, Inst Biomed Informat, Bioinformat Ctr, Henan Prov Engn Ctr Tumor Mol Med,Sch Basic Med Sc, Kaifeng 475004, Henan, Peoples R China

[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou 450052, Henan, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2023年 / 16卷 / 01期

关键词：

Non-Hodgkin's lymphoma; Bispecific antibody; CD20; CD3; EPCORE NHL-1;

D O I：

10.1186/s13045-023-01488-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 x CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20(+) NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 x CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).

引用

页数：4

共 50 条

[21] Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)
Gupta, Pankaj
Goldenberg, David M.
Rossi, Edmund A.
Cardillo, Thomas M.
Byrd, John C.
Muthusamy, Natarajan
Furman, Richard R.
Chang, Chien-Hsing
BLOOD, 2011, 118 (21) : 275 - 275
[22] Anti-lymphoma effects of recombinant bispecific monoclonal antibodies (bsMAbs) against CD20 and CD22 antigens
Qu, Z.
Shi, V.
Delaney, D. L.
Hansen, H. J.
Chang, C-H
Goldenberg, D. M.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (04) : 403 - 403
[23] Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting
Han, Lijie
Xing, Haizhou
Cao, Weijie
Song, Yongping
Jiang, Zhongxing
Yu, Jifeng
EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (04) : 221 - 223
[24] T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody
Saleh, Layla M.
Mhibik, Maissa
Playa-Albinyana, Heribert
Sun, Clare
Pleyer, Christopher
Wiestner, Adrian
BLOOD, 2024, 144 : 3231 - 3232
[25] CD3 and CD20 Immunohistochemical Staining Patterns of Bone Marrow-Infiltrating Malignant Lymphoma Cells
Lee, Eun Jin
Kim, Miyoung
Kim, Han-Sung
Kang, Hee Jung
Kim, Hyo Jung
Min, Soo Kee
Lee, Young Kyung
ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2017, 47 (02): : 136 - 143
[26] The Evaluation of CD3, CD 5, CD10, CD 19, and CD20 Markers in the Differential Diagnosis of the Lymphoma Subtypes in Sudanese Patients
Abdelwadoud, Mohamed Elfatih
Ahmed, Nabawia S.
Waggiallah, Hisham Ali
Alhaj, Hadia
INTERNATIONAL JOURNAL OF BIOMEDICINE, 2021, 11 (04) : 493 - 497
[27] Heterodimerization of CD74 and CD20 by two hexavalent, bispecific, anti-CD20/CD74 antibodies leads to potent cytotoxicity in mantle cell lymphoma
Gupta, Pankaj
Rossi, Edmund A.
Goldenberg, David M.
Chang, Chien-Hsing
CANCER RESEARCH, 2011, 71
[28] Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting
Sun, Hao
Xing, Haizhou
Han, Lijie
Song, Yongping
Jiang, Zhongxing
Liu, Yanyan
Yu, Jifeng
EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (05) : 321 - 326
[29] Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (αEpCAM x αCD3)
Riesenberg, R
Buchner, A
Pohla, H
Lindhofer, H
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2001, 49 (07) : 911 - 917
[30] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
Sisi Wang
Lijun Peng
Wenqian Xu
Yuebo Zhou
Ziyan Zhu
Yushan Kong
Stewart Leung
Jin Wang
Xiaoqiang Yan
Jian-Qing Mi
Frontiers of Medicine, 2022, 16 : 139 - 149

← 1 2 3 4 5 →